These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22236191)

  • 1. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
    Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
    Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
    Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
    Narita Y; Taniguchi H; Komori A; Nitta S; Yamaguchi K; Kondo C; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):409-16. PubMed ID: 24322376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.
    Inanc M; Er O; Karaca H; Berk V; Ozkan M; Dikilitas M; Elmali F
    J BUON; 2013; 18(2):391-7. PubMed ID: 23818351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
    Jia J; Zhang P; Gou M; Yang F; Qian N; Dai G
    Dis Markers; 2019; 2019():6812045. PubMed ID: 30805037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
    Cassidy J
    Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer.
    Kim HJ; Lee KW; Kim YJ; Oh DY; Kim JH; Im SA; Lee JS
    Acta Oncol; 2009; 48(3):385-90. PubMed ID: 18855156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature.
    de Andrade DP; Lima JP; Lima AD; Sasse AD; dos Santos LV
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S15-7. PubMed ID: 21768792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].
    Kashiwagi S; Maeda K; Fuyuhiro Y; Nagahara H; Kimura K; Amano R; Noda E; Kubo N; Tanaka H; Muguruma K; Yashiro M; Yamada N; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1936-8. PubMed ID: 22202244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
    Dirican A; Kucukzeybek Y; Alacacioglu A; Varol U; Aksun S; Bayoglu IV; Demir L; Coban E; Sutcu R; Tarhan MO
    Med Oncol; 2014 Apr; 31(4):905. PubMed ID: 24596030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
    Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.
    Blackwell K; Hurwitz H; Liebérman G; Novotny W; Snyder S; Dewhirst M; Greenberg C
    Cancer; 2004 Jul; 101(1):77-82. PubMed ID: 15221991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
    Nagai Y; Beppu T; Sakamoto Y; Miyamoto Y; Hayashi H; Nitta H; Imai K; Masuda T; Okabe H; Hirashima K; Imamura Y; Baba Y; Chikamoto A; Baba H
    Anticancer Res; 2014 Oct; 34(10):5529-35. PubMed ID: 25275051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
    Matsusaka S; Mishima Y; Suenaga M; Terui Y; Kuniyoshi R; Mizunuma N; Hatake K
    Cancer; 2011 Sep; 117(17):4026-32. PubMed ID: 21858803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
    Baraniskin A; Munding J; Schulmann K; Meier D; Porschen R; Arkenau HT; Graeven U; Schmiegel W; Tannapfel A; Reinacher-Schick A
    Clin Colorectal Cancer; 2011 Mar; 10(1):24-9. PubMed ID: 21609932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.